Pharsight

1. Exjade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6596750	NOVARTIS	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	Jun, 2017 (6 years ago)
US6465504	NOVARTIS	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	Apr, 2019 (5 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-239)	Dec 12, 2021
Orphan Drug Exclusivity(ODE-39)	Jan 23, 2020
M(M-241)	Jul 24, 2022
M(M-263)	Jul 23, 2023
Orphan Drug Exclusivity(ODE)	Nov 02, 2012
New Indication(I-665)	Jan 23, 2016

Market Authorisation Date: 02 November, 2005

Treatment: Method of treating chronic iron overload

Dosage: TABLET, FOR SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
125 mg, 250 mg, and 500 mg	28 Oct, 2011	1	26 Jan, 2016	05 Apr, 2019	Eligible

Application	Filing Date	Opposition Party	Legal Status

EP14710654A	2019-07-31	INVOKAT Intellectual Property Services	Patent maintained as amended
EP14710654A	2019-07-30	HGF Limited	Patent maintained as amended
EP14710654A	2019-07-23	Teva Pharmaceutical Industries Ltd	Patent maintained as amended
EP16188627A	2018-09-20	HGF Limited	Granted and Under Opposition
EP16188627A	2018-09-20	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6596750	NOVARTIS PHARMS CORP	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	Jun, 2017 (6 years ago)
US6465504	NOVARTIS PHARMS CORP	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	Apr, 2019 (5 years ago)
US9283209	NOVARTIS PHARMS CORP	Oral formulations of deferasirox	Nov, 2034 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-241)	Jul 24, 2022
Orphan Drug Exclusivity(ODE)	Jan 23, 2020
M(M-239)	Dec 12, 2021
Orphan Drug Exclusivity(ODE-39)	Jan 23, 2020
M(M-263)	Jul 23, 2023

Market Authorisation Date: 30 March, 2015

Treatment: Method of treating chronic iron overload

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
90 mg and 360 mg	19 Oct, 2015	1		05 Apr, 2019	Extinguished
180 mg	21 Apr, 2016	1	13 Dec, 2019	21 Nov, 2034	Eligible

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6465504	NOVARTIS	Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators	Apr, 2019 (5 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-241)	Jul 24, 2022
M(M-239)	Dec 12, 2021
M(M-263)	Jul 23, 2023

Market Authorisation Date: 18 May, 2017

Treatment: NA

Dosage: GRANULE;ORAL